For instance, it has been shown that sex and body mass index are associated with heterogeneity in the treatment and safety signal of thiazolidinediones and sulfonylureas [96], whereas insulin resistance has been associated with significant differences in the glycemic response to dipeptidyl peptidase 4 (DPP-4) inhibitors [97]. Here, DPP4 is linked to Insulin resistance.